https://www.selleckchem.com/pr....oducts/incb054329.ht
31). There was no significant effect on decline in eGFR events (RR 0.34; 95% CI 0.09-1.23), proteinuria (standardized mean difference -0.32; 95% CI -1.08 to 0.43), all-cause mortality events (RR 0.90; 95% CI 0.40-2.02) and cardiovascular (CV) events (RR 1.03; 95% CI 0.32-3.37) compared with the control groups. Based on the available and low-to-moderate certainty evidence, oral alkali drug therapy might potentially reduce the risk of kidney failure events, but no benefit in reducing all-cause mortality events, CV events, decline in eG
Like
Comment
Share
